Ranibizumab for choroidal neovascularization in fundus flavimaculatus.
OBJECTIVE
To report the features of a case with late-onset fundus flavimaculatus (FFM) complicated by choroidal neovascularization (CNV) and treated with ranibizumab.


METHODS
Retrospective interventional case report.


METHODS
A 51-year-old woman presented with right eye decreased vision. Fundus flavimaculatus with CNV was diagnosed by electroretinography and fluorescein angiography.


RESULTS
Two intravitreal injections of ranibizumab were needed for the treatment. At the end of follow-up (9 months) no leakage was observed and visual acuity improved.


CONCLUSIONS
Choroidal neovascularization is a rare complication of FFM. Ranibizumab, an anti-VEFG drug, stopped neovascularization and improved final visual acuity in this case, so it must be considered in the treatment of CNV in late onset FFM.
From Fundación Oftalmológica del Mediterráeno, Valencia, Spain.
Amparo Navea
AN
Tejerina
Maria
M
García-Pous
Elena Palacios
EP
Pozos
M Carmen Desco
MC
Esteban
Jorge Mataix
JM
Boronat